A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Study of ASTX029 in Subjects With Advanced Solid Tumors
Sponsor: Astex Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAS1827
U.S. Govt. ID: NCT03520075
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test the safety of the study drug, ASTX029, and to find the appropriate dose of this experimental drug to use in this and other studies. The drug that will be given to you in this study, ASTX029, is investigational. This means it has not been approved for treatment of any disease, including cancer.
Do You Qualify?
Do you have an advanced solid tumor that is unresectable or metastatic? Yes No
Is your tumor able to be biopsied? Yes No
Have you received an extracellular signal-reduced kinase (ERK) inhibitor? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162